Centronuclear Myopathy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Types (Myotubular Myopathy, Autosomal Centronuclear Myopathies, and Others), By Treatment (Night-time Ventilation, Gastrostomy, Physiotherapy, Antibiotics, and Others), By Diagnosis (Muscle Biopsy, Molecular Testing, and Others), By End Users (Hospitals, Specialty Clinics, Homecare, Others) and Region Forecast 2020-2031

Centronuclear Myopathy Market size was valued at US$ 1,510.8 million in 2024 and is expected to reach US$ 2,227.0 million by 2031, growing at a significant CAGR of 5.7% from 2025-2031. Centronuclear myopathies (CNM) are a group of congenital myopathies, that occur mainly because of mutation in the MTM1 gene, where cell nuclei are abnormally located in the center of muscle cells instead of their normal location at the periphery, symptoms include severe hypotonia, hypoxia requiring breathing assistance, and scaphocephaly. As per a research report, the X-liked form of centronuclear myopathy has an incidence rate of 1 per 50,000 male births. The rise in the demand and need for novel therapeutics will act as the growth driver for the market. However, the limited availability of medicinal treatment options due to the low prevalence of centronuclear myopathy is the factor hindering the market growth. Financial support from the government and an increase in strategic collaborations between the market players are huge growth opportunities for the expansion of the market.

Key Developments

• In Nov 2021, Dynacure and Nippon Shinyaku entered into a long-term strategic development and commercialization agreement for Dynacure’s DYN-101, for the treatment of centronuclear myopathies.
• In Jan 2023, ARMGO Pharma’s ARM 210 was in phase-I development for congenital structural myopathies in the USA.